APTAMATRIX, INC. — Department of Defense STTR Phase I: ABSTRACT: This phase I STTR project is a proof of concept study for developing near real-

Description

ABSTRACT: This phase I STTR project is a proof of concept study for developing near real-time, nanoparticle based sensors that detect the presence of specified toxins, pathogens, proteins, metabolites and small molecules. The specificity and sensitivity of this"nanosensor"is imparted by aptamer recognition that is engineered into a novel, patented technology we termed as an Alloswitch. These Alloswitch sensors will be embedded in nanoparticles to create a"nanosensor"that are capable of long term storage, easy to administer to patients, and facilitate entry and uptake by cells. BENEFIT: There is a clear need for detection of bio-terror agents and new options for treatment of affected military and civilian personnel. There are also military and civilian needs for rapid diagnostics in bodily fluids and cells. Our nanosensor platform will enable rapid detection of targeted microorganisms, viruses, proteins, and metabolites, and also provide therapeutic options. Detection can be made in bodily fluids or specifically chosen cell types. Success in these applications will be of tremendous commercial and societal value.